SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

ACLARIS THERAPEUTICS ANNOUNCES TOP LINE PHASE 2 RESULTS FOR ITS ANTI-TSLP MONOCLONAL ANTIBODY BOSAKITUG (ATI-045) IN ATOPIC DERMATITIS (AD)

ACLARIS THERAPEUTICS ANNOUNCES TOP LINE PHASE 2 RESULTS FOR ITS ANTI-TSLP MONOCLONAL ANTIBODY BOSAKI

ACRS

Related stories